Screener
Gyre Therapeutics, Inc. GYRE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 4:16 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-214676
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Deferred financing costs | — | (121) |
| Proceeds from the exercise of stock options | 21 | 956 |
| Proceeds from the issuance of common stock in ATM Program | — | 509 |
| Net cash provided by financing activities | 21 | 1,344 |
| Effect of exchange rate changes on cash | 285 | 50 |
| Net increase in cash | 431 | 3,232 |
| Cash at beginning of the period | 37,070 | 11,813 |
| Cash at end of period | $37,501 | $15,045 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s financing cash flow?
- Gyre Therapeutics, Inc. (GYRE) reported financing cash flow of $21K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Gyre Therapeutics, Inc.'s financing cash flow decreased by 98.4% year-over-year, from $1.34M to $21K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s financing cash flow?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s financing cash flow has grown at a 212.3% compound annual growth rate (CAGR), from $2.5M to $24.38M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Gyre Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude